Kalray Unveils Its K200-LP Latest Acceleration Card for Data Centers
16.6.2021 08:30:00 EEST | Business Wire | Press release
Kalray (Euronext Growth Paris: ALKAL), a leading provider in the new generation of processors specialized in Intelligent Data Processing from Cloud to Edge, today unveils its new K200-LP™ acceleration card. K200-LP™ is a new member of Kalray’s fully programmable multi-purpose acceleration card family, based on its unique MPPA® processor, and offering an unprecedented level of performance and targeting the booming NVMe based storage market as its first implementation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210615006166/en/
Kalray's K200-LP Acceleration Card (Photo: Kalray)
The explosion of data, driven by demanding services and applications using AI and data analytics, is putting a lot of pressure on Cloud and Edge Data Center’s networking and storage to feed the demanding compute intensive resources. The primary needs are to reduce latency, enhance bandwidth and IOPs1 performance as well as offloading host CPUs, at best cost.
Data centers are looking for solutions that enable high performance, low power, cost effectiveness and openness to scale and match demand on data availability. The K200-LP™ acceleration card is Kalray’s solution to address these exacting demands for their data center customers.
Eric Baissus, President and CEO of Kalray, said: “We are proud to unveil our new K200-LP™ acceleration card, based on our MPPA® processor. This family of Ethernet/PCIe acceleration cards are natively capable of managing multiple workloads with no bottleneck to enable smarter, more efficient, and energy-wise applications on Cloud and Edge data centers. To address the new generation of storage array solutions for Cloud and Edge, K200-LP™ is a game changer solution in terms of performance per Watt and per dollar.”
To improve and optimize overall IT infrastructures, the industry has moved increasingly towards disaggregated storage. Put simply, separating compute resources and storage resources.
1 IOPS is the numbers of Input/Output operations per second and is a performance measurement used to characterize computer storage devices.
Most advanced All-Flash-Array solutions today use multiple adapter cards around a x86 that runs storage services. Kalray manages to run all the critical functions of a disaggregated storage appliance on one single chip: the Kalray MPPA® processor. Advanced Data Processing Units (DPU) like MPPA® and associated acceleration cards can run, efficiently and on a cost-optimized manner versus traditional x86, new protocols such as NVMe and NVMe-over-Fabric to access and unleash the full capability of SSDs wherever they are located in the Data Center as if there were locally attached.
Whereas the industry has defined a new NVMe protocol to support the latest generation of ultra-fast storage devices, existing traditional technologies are not capable of exposing the full capability of NVMe-based SSDs. Kalray’s K200-LP™ smart storage card has been built from the ground-up to support those breaking through data protocols. Based on Kalray MPPA’s processor, K200-LP™ is also the perfect solution for storage array appliance makers and cloud service providers, to build their next generation of storage appliances in terms of performance per Watt per $.
Kalray’s K200-LP™ acceleration card is a low-profile, 2x 100GB ethernet, PCIe Gen4 card that can deliver more than 2 MIOPS and 12 GB/s per card (both RoCE and TCP) with a latency as low as 30 microseconds. K200-LP™ has been developed by Kalray and is manufactured by Taiwanese Wistron, one of the largest manufacturers of electronic cards and data center servers in the world.
Kalray’s K200-LP™ smart storage card and associated tools are available now.
ABOUT KALRAY
Kalray (Euronext Growth Paris - FR0010722819 - ALKAL) is a fabless semiconductor company, leading provider in a new generation of processors specialized in Intelligent Data Processing from Cloud to Edge. Kalray MPPA® Intelligent Processors are able to capture and analyze on the fly massive data flows, and interact in real time with the outside world. These processors are capable of running demanding AI algorithms and simultaneously a wide set of different processing and control tasks such as intensive mathematical algorithms, signal processing, network or storage software stacks. Kalray’s Intelligent Processors can be deployed in fast-growing sectors from Cloud to Edge: modern data centers, 5G telecom networks, autonomous vehicles, healthcare equipment, industry 4.0, drones and robots… Kalray’s offering includes processors, acceleration cards and a software suite, for a broad spectrum of customers such as next generation data center equipment manufacturers and service providers, system integrators and consumer product manufacturers such as car makers. Founded in 2008 as a spin-off of CEA French lab, Kalray counts among its investors: Alliance Venture (Renault-Nissan-Mitsubishi), Safran, NXP Semiconductors, CEA and Bpifrance. Read more at: www.kalrayinc.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210615006166/en/
Contact information
INVESTORS
Eric BAISSUS
contactinvestisseurs@kalrayinc.com
+33 (0)4 76 18 90 71
ACTUS finance & communication
Jérôme FABREGUETTES-LEIB
kalray@actus.fr
+33 1 53 67 36 78
MEDIA
Loic HAMON
communication@kalrayinc.com
+33 (0)4 76 18 90 71
ACTUS finance & communication
Serena BONI
sboni@actus.fr
+33 (0)4 72 18 04 92
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
